The transition that changes your metabolism – and the evidence-based approach to protecting it

The Metabolic Turning Point

Many women arrive at perimenopause with a clean bill of metabolic health – normal blood sugar, normal cholesterol, no particular reason to worry about diabetes. Then the transition begins, and something measurable changes in the background of their physiology. Blood sugar that was reliably normal now spikes higher after meals. Energy levels become unpredictable. Weight accumulates around the abdomen despite no change in eating. A routine blood test returns with fasting glucose in the “borderline” range, and the clinician mentions “prediabetes” for the first time.

The decline of estrogen during menopause naturally lowers your metabolic rate and makes your cells more resistant to insulin, increasing the risk of type 2 diabetes even if your diet hasn’t changed.

This is the metabolic transition of menopause – and it is one of the most consequential and least discussed health changes of this life stage. It is not inevitable, and it is not irreversible. But it requires understanding, and it requires an evidence-based response.

Part 1: Why Menopause Changes Your Metabolism

Estrogen as Metabolic Protector

Before the menopausal transition, premenopausal women have significantly lower rates of type 2 diabetes, metabolic syndrome, and insulin resistance than age-matched men. This protection is not incidental – it is directly mediated by estrogen.

Insulin resistance results when peripheral tissues – including adipose tissue, skeletal muscle, and the liver – do not respond appropriately to insulin, causing the ineffective uptake of glucose from the bloodstream. This represents a risk factor for the development of type 2 diabetes mellitus. Men are more susceptible to metabolic syndrome than premenopausal women; however, protection in women is significantly reduced when estrogen levels decrease. When compared with premenopausal women, postmenopausal women and the respective age-matched men present with increased insulin resistance, as measured by the homeostatic model assessment-insulin resistance (HOMA-IR).

Estrogen protects metabolic function through multiple simultaneous mechanisms:

Skeletal muscle glucose uptake. Estrogen directly upregulates GLUT4 transporter expression in skeletal muscle – the primary mechanism by which glucose is cleared from the bloodstream after meals. When estrogen falls, GLUT4 expression declines, and the same meal produces a higher and more sustained blood glucose elevation.

Pancreatic beta-cell function. Estrogen maintains the health, survival, and insulin secretory capacity of the pancreatic beta cells – the cells responsible for producing insulin. Large randomised controlled trials suggest that menopausal hormone therapy using estrogens delays the onset of type 2 diabetes in women. MHT improves beta-cell insulin secretion, glucose effectiveness, and insulin sensitivity, as measured in clinical settings.

Hepatic glucose production. Estrogen suppresses the liver’s tendency to produce glucose even when blood glucose is already adequate (hepatic gluconeogenesis). When estrogen falls, the liver becomes less efficiently regulated, producing excess glucose during fasting states and contributing to elevated fasting blood sugar.

Adipokine balance. Estrogen supports the production of adiponectin – the adipokine (fat-cell hormone) that sensitizes tissues to insulin – and suppresses resistin – the adipokine that promotes insulin resistance. When estrogen falls, this adipokine balance shifts unfavorably.

Visceral fat and the inflammatory cascade. Menopause causes fat storage to shift from the hips to the abdomen (visceral fat). This belly fat is metabolically active and further worsens insulin resistance and inflammation. Your fat distribution shifts during perimenopause and menopause. Menopause causes fat storage to shift from the hips to the abdomen (visceral fat). This belly fat is metabolically active and further worsens insulin resistance and inflammation. Visceral adipose tissue releases pro-inflammatory cytokines (IL-6, TNF-α) and free fatty acids that directly impair insulin receptor signaling in the liver and muscle.

The Cascade: How Insulin Resistance Progresses

Insulin is a hormone that acts like a key. Its job is to unlock your cells so that sugar (glucose) from the food you eat can enter and be used for energy. When you have healthy estrogen levels, this process usually works smoothly. However, as estrogen declines, your cells can become “resistant” to insulin’s signal. The key no longer turns the lock easily. When your cells resist insulin, your pancreas has to work overtime to pump out more insulin to get the blood sugar down. Over time, this pattern can lead to chronically high blood sugar levels and eventual exhaustion of the pancreas.

This progression – from normal insulin sensitivity through increasing resistance to compensatory hyperinsulinemia to eventual beta-cell exhaustion – is the pathway to type 2 diabetes. Menopause does not cause this progression in every woman, but it measurably accelerates the trajectory in those with pre-existing risk factors. Visceral obesity and diminished estrogen levels during the menopausal phase are associated with unfavorable metabolic changes, resulting in insulin resistance and increased risk of type 2 diabetes mellitus.

The Evidence on Absolute Risk: A Nuanced Picture

The science in this area has been clarified by a landmark 2026 study published in Menopause (the journal of The Menopause Society). Despite increases in fat and insulin resistance during the menopause transition, a large-scale study found no independent or clinically significant relationship between age or type of menopause and the onset of diabetes. The metabolic risk factors that accumulate during menopause – increased fat and insulin resistance – do not automatically translate to diabetes unless other risk factors are present.

Women aged younger than 45 years who experience early menopause are at higher risk of coronary heart disease and stroke; and a systematic review confirmed that early and premature menopause are associated with increased risk of type 2 diabetes, with women whose menopause occurred after age 45 having significantly decreased risk compared to those with earlier menopause.

The clinical implication: the menopausal transition creates a metabolic vulnerability – an environment in which diabetes risk is elevated – but it does not predetermine diabetes. This vulnerability responds to intervention. The response must begin early and be sustained.

Part 2: Recognizing the Signs – The Clinical Picture of Insulin Resistance

Insulin resistance during perimenopause is frequently subclinical for years before it meets the diagnostic threshold for prediabetes or type 2 diabetes. Recognizing its early markers is the most important preventive opportunity.

Symptoms that may indicate developing insulin resistance:

• Persistent fatigue, particularly after carbohydrate-containing meals
• Energy crashes in the early afternoon
• Increased hunger, particularly for carbohydrates and sweet foods, despite adequate food intake
• Difficulty losing weight despite consistent dietary effort
• Progressive abdominal weight gain
• Brain fog, particularly after meals
• Increased thirst and urination (later presentation)
• Skin tags (acrochordon) – soft, benign skin growths particularly in the neck creases and armpits are associated with hyperinsulinaemia
• Dark, velvety skin patches (acanthosis nigricans) – particularly in neck creases, armpits, and groin – a direct skin manifestation of hyperinsulinaemia

Blood tests to request:

• Fasting glucose – below 5.5 mmol/L (99 mg/dL) is normal; 5.6–6.9 mmol/L (100–125 mg/dL) is prediabetes; 7.0 mmol/L+ (126 mg/dL) is diabetes
• HbA1c – reflects average blood glucose over the preceding 2–3 months; below 5.7% is normal; 5.7–6.4% is prediabetes; 6.5%+ is diabetes
• Fasting insulin – not routinely requested but highly informative; elevated fasting insulin with normal fasting glucose is the earliest detectable sign of insulin resistance (the pancreas is still compensating)
• HOMA-IR – calculated from fasting glucose and fasting insulin; a score above 2 indicates insulin resistance in most clinical models
• Fasting lipid panel – insulin resistance characteristically produces elevated triglycerides, low HDL cholesterol, and small dense LDL particles that are not captured by total cholesterol measurement alone
• Liver function tests – insulin resistance drives non-alcoholic fatty liver disease; elevated ALT may be the first laboratory sign
• Waist circumference – the most accessible and most predictive single measurement of visceral adiposity and metabolic risk; above 80 cm in women constitutes elevated metabolic risk; above 88 cm constitutes high risk

Part 3: The Evidence-Based Treatment Approach

1. Dietary Strategy: The Most Powerful Single Intervention

Lifestyle interventions with small weight loss (7–10%), 150 minutes of weekly moderate-intensity exercise, and behavioral therapy approach can be highly effective in preventing and treating type 2 diabetes. The dietary component is the highest-leverage element of this combination.

Mediterranean dietary pattern: The gold standard for diabetes prevention

The Mediterranean and plant-based diets are well-established paradigms that have benefited both the treatment and prevention of type 2 diabetes. The Mediterranean diet plus exercise and support reduced the risk of diabetes by 31% in a landmark 2025 study.

The evidence base for the Mediterranean diet in diabetes prevention and insulin sensitivity improvement is the most consistent of any dietary pattern across multiple systematic reviews and meta-analyses. Its key features for metabolic benefit: high-fiber vegetables and legumes (reducing glycemic load and promoting satiety), whole rather than refined grains, oily fish (providing omega-3 fatty acids that reduce inflammation and improve insulin receptor function), olive oil (with its oleocanthal anti-inflammatory compounds and ability to reduce postprandial glycaemia), nuts (which blunt postprandial glucose spikes), and limited ultra-processed foods, added sugar, and refined carbohydrates.

Low-carbohydrate dietary approaches

Decreasing carbohydrates in meals significantly improves glycemic and insulin responses, but the extent of this reduction should be individualized, patient-centered, and monitored. Low-carbohydrate diets show short-term benefits for weight management and HbA1c reduction, with some evidence that they produce more rapid initial improvement in glycemic control than the Mediterranean diet – particularly in women with established insulin resistance or prediabetes.

A 16-week comparative trial found that both the Mediterranean diet and a moderate low-carbohydrate diet produced meaningful improvements in HbA1c and fasting glucose, with the low-carbohydrate approach producing marginally greater short-term glycemic benefit and the Mediterranean diet showing better lipid and cardiovascular outcomes at longer follow-up.

The low glycemic load principle: Applicable regardless of dietary pattern

Consuming foods of low density such as vegetables, salads, or soups consumed first, followed by protein, and then by starchy foods leads to significantly ameliorated glycemic and insulin responses. Changing the sequence of nutrients within a meal – without changing its composition – consistently reduces the postprandial glucose spike by 20–40%. This “food order” strategy is entirely accessible, costs nothing, and produces immediate benefit.

Chrononutrition: When you eat matters as much as what you eat

Chrononutrition is an integral part of metabolism, pancreatic function, and hormone secretion. Eating most calories and carbohydrates at lunch time and early afternoon, avoiding late evening dinner, and keeping a consistent number of daily meals play a pivotal role for postprandial glycaemia and insulin sensitivity.

Evening and late-night eating produces significantly greater postprandial glycaemia and insulin demand than the identical meal consumed at noon. This reflects the circadian rhythm of insulin sensitivity – which peaks in the morning and declines through the day. Aligning the largest and most carbohydrate-rich meals with the morning and midday period, and keeping evening meals smaller and lower in carbohydrate, directly improves metabolic parameters in perimenopausal and postmenopausal women.

Time-restricted eating (intermittent fasting)

Intermittent fasting and Mediterranean diet have been shown to reduce visceral adiposity and promote metabolic health among menopausal women. Studies have shown that time-restricted feeding can aid in reducing visceral fat and improving metabolic markers, such as glucose and lipid profiles, by enhancing insulin sensitivity. A 10–12 hour eating window (e.g., eating between 8am and 6pm or 8am and 8pm) is a practical and evidence-supported approach that most women can sustain without significant dietary restriction.

Specific foods with direct evidence for insulin sensitivity:

• Vinegar (1–2 tablespoons with or before meals) – acetic acid reduces postprandial glucose by inhibiting amylase (the enzyme that breaks down starch) and slowing gastric emptying. A consistent evidence base across multiple trials supports a meaningful reduction in postprandial glucose with habitual vinegar consumption
• Nuts – a handful of mixed nuts before a carbohydrate-containing meal significantly blunts the glycemic response, through their fiber, fat, and protein content
• Legumes – lentils, chickpeas, and beans have among the lowest glycemic indices of any carbohydrate food and directly improve HbA1c when substituted for higher-glycemic carbohydrates
• Yoghurt and fermented foods – probiotics and synbiotics support the gut microbiome populations that produce short-chain fatty acids with direct insulin-sensitizing effects. Meta-analyses of probiotics consistently show modest but significant improvements in fasting glucose and insulin sensitivity
• Whey protein – consumed before meals, whey protein produces a strong GLP-1 and insulin cephabic response that significantly reduces the subsequent postprandial glucose spike, particularly in women with insulin resistance

2. Exercise: The Second Pillar of Metabolic Protection

A combination of dietary modification and physical activity, particularly Mediterranean and plant-based diets coupled with combined aerobic and resistance exercise, appears to be the most effective strategy for the prevention and management of type 2 diabetes.

Resistance training is uniquely valuable for insulin resistance because skeletal muscle is the largest organ of glucose disposal in the body – accounting for 70–80% of postprandial glucose uptake. Building and maintaining muscle mass is therefore a direct insulin-sensitizing intervention. Resistance training improves GLUT4 expression, reduces visceral fat through increased resting metabolic rate, and improves insulin sensitivity for 24–48 hours following each session.

Aerobic exercise improves insulin sensitivity through different mechanisms: it depletes muscle glycogen stores (which are then replenished from circulating glucose), stimulates AMPK (an enzyme that promotes glucose uptake independently of insulin), and reduces inflammation through adipokine and myokine signaling.

HIIT (High-Intensity Interval Training) – emerging evidence shows particularly strong effects on insulin sensitivity per unit of exercise time. 20–30 minute HIIT sessions two to three times weekly produce insulin sensitivity improvements comparable to 150 minutes of moderate continuous exercise in head-to-head comparisons in women with insulin resistance.

Post-meal walking – a specific and underutilized strategy: a 10–15 minute walk within 30–60 minutes of a meal reduces the postprandial glucose spike by 20–30%. This works through direct mechanical stimulation of muscle glucose uptake during the postprandial window when blood glucose is highest.

The evidence-based exercise prescription for insulin resistance prevention and management in menopausal women: two to three resistance training sessions weekly, 150 minutes of moderate aerobic activity, and post-meal walking after at least two main meals daily. The combination of strength and aerobic exercise produces superior metabolic outcomes compared to either alone.

3. Weight Loss: Even Small Amounts Matter

Weight loss is important for the treatment of insulin resistance, and it can be achieved by many approaches, such as low-fat, low-carbohydrate, and Mediterranean-style diets. Critically, the effect of weight loss on insulin sensitivity is non-linear – even modest weight loss (5–7% of body weight) produces disproportionately large improvements in insulin sensitivity, often reducing fasting glucose by 10–15% and HbA1c by 0.5–1%.

This non-linearity occurs because visceral fat (the most metabolically dangerous fat depot) is disproportionately lost in early weight loss – even small absolute reductions in visceral fat mass produce large improvements in hepatic insulin sensitivity and inflammatory cytokine profiles.

4. Sleep Optimization

Sleep deprivation impairs insulin sensitivity through multiple well-documented mechanisms: it increases cortisol (which directly promotes insulin resistance), reduces glucose clearance from the bloodstream, increases appetite for high-calorie foods, and impairs the overnight glucose regulation that normally produces the physiological “dawn phenomenon” appropriately without hyperglycemia.

For perimenopausal women, this creates a particularly vicious cycle: night sweats disrupt sleep, sleep disruption worsens insulin resistance, worsened insulin resistance promotes weight gain and fatigue, fatigue reduces exercise capacity, and reduced exercise further worsens insulin resistance. Treating the underlying cause of sleep disruption – vasomotor symptoms, insomnia, anxiety – is a direct metabolic intervention.

5. Stress Reduction and Cortisol Management

Cortisol directly promotes insulin resistance through its effects on the liver (stimulating hepatic gluconeogenesis), muscle (reducing GLUT4 expression), and adipose tissue (promoting visceral adipogenesis). The elevated cortisol reactivity of perimenopause creates a sustained metabolic environment of increased insulin resistance. Mindfulness, yoga, social connection, and adequate recovery between exercise sessions all reduce cortisol and, by extension, improve insulin sensitivity.

6. Specific Supplements with Evidence for Insulin Sensitivity

Magnesium – magnesium is required as a cofactor for over 300 enzymatic processes, including insulin receptor signaling and glucose transporter function. Magnesium deficiency (prevalent in 40–60% of postmenopausal women) is independently associated with insulin resistance and elevated diabetes risk. Food sources: pumpkin seeds, dark leafy greens, almonds, dark chocolate. Supplemental magnesium glycinate (300–400 mg daily) is well-tolerated and evidence-supported for improving fasting glucose and insulin sensitivity.

Berberine – an alkaloid compound from several plants that activates AMPK (the same pathway activated by exercise and metformin), reduces hepatic glucose production, and improves insulin sensitivity. A 2024 systematic review confirmed significant reductions in fasting glucose, HbA1c, and HOMA-IR with berberine supplementation in people with type 2 diabetes and prediabetes, with an effect size approaching that of metformin in head-to-head comparisons. 500 mg twice daily with meals is the most evidence-supported protocol. Not appropriate during pregnancy and should be discussed with a clinician before use.

Chromium picolinate – supports insulin receptor function; modest evidence for improving fasting glucose and insulin sensitivity at doses of 200–600 mcg daily.

Alpha-lipoic acid – an antioxidant with direct insulin-sensitizing properties; evidence for improving HOMA-IR and reducing fasting glucose at 600–1,200 mg daily, particularly in women with metabolic syndrome.

Inositol – specifically myo-inositol (and the combination myo-inositol/D-chiro-inositol) improves insulin signaling at the cellular level; originally studied in PCOS (polycystic ovary syndrome) but with a growing evidence base in menopausal metabolic syndrome. 2g myo-inositol twice daily is the evidence-supported dose.

Fiber supplements (psyllium husk, beta-glucan, inulin) – soluble fiber ferments in the colon to produce short-chain fatty acids with direct insulin-sensitizing properties, reduces postprandial glucose peaks, and slows gastric emptying. Psyllium husk (5–10g before meals with water) has the strongest individual evidence for postprandial glucose reduction.

7. Hormone Therapy: The Most Mechanistically Direct Intervention

A new meta-analysis of 17 unique randomized controlled trials that covered more than 29,000 participants between 1998 and 2024 found that hormone therapy significantly reduced insulin resistance in healthy postmenopausal women without metabolic diseases including diabetes, hypertension, and cardiovascular diseases.

Menopausal hormone therapy has favorable results in glucose metabolism. For women with prediabetes or significant metabolic risk, MHT provides a mechanism-targeted approach – directly restoring estrogen’s insulin-sensitizing effects on skeletal muscle, pancreatic beta-cell function, hepatic glucose regulation, and visceral fat redistribution.

Transdermal estrogen specifically deserves attention in the metabolic context: unlike oral estrogen, transdermal delivery avoids first-pass hepatic metabolism and does not produce the same hepatic inflammatory effects that can partially offset the metabolic benefits of oral estrogen. Transdermal estradiol combined with oral micronized progesterone (which, unlike synthetic progestins, does not worsen insulin resistance) represents the most metabolically favorable MHT combination.

Studies show that estrogen therapy during menopause can attenuate visceral fat gain by as much as 60%, improve insulin sensitivity, and even help increase lean muscle mass – the tissue most critical for glucose disposal. MHT is neither FDA-approved nor appropriate as a standalone diabetes prevention drug, but for women with insulin resistance who have other indications for MHT (vasomotor symptoms, bone health, mood), the metabolic benefits are a well-documented secondary benefit.

8. GLP-1 Receptor Agonists: The Emerging Pharmacological Frontier

GLP-1 receptor agonists (semaglutide, tirzepatide, dulaglutide) represent the most significant advance in metabolic pharmacology in a generation. Originally developed for type 2 diabetes, they now have approval for weight management and are being studied across the full metabolic risk spectrum. Their mechanisms of action are directly relevant to the menopausal metabolic context: they stimulate glucose-dependent insulin secretion, suppress glucagon, reduce hepatic glucose production, promote satiety, reduce visceral fat specifically, and slow gastric emptying.

The 2024 Menopause study showing that semaglutide plus hormone therapy produced significantly greater weight loss and metabolic improvement than semaglutide alone establishes this combination as the most potent pharmacological approach for postmenopausal women with significant metabolic risk. For women with established prediabetes or metabolic syndrome who have not achieved adequate response to lifestyle intervention, GLP-1 receptor agonists – under appropriate medical supervision – represent a genuine clinical option.

Part 4: The Practical Framework

Daily non-negotiables:

• Eat the largest and most carbohydrate-rich meal at breakfast or lunch, not dinner
• Include protein in every meal (25–40 g per meal)
• Post-meal walking: 10–15 minutes after at least two meals daily
• 30+ grams of fibre from food (legumes, vegetables, whole grains)
• Adequate sleep: treat causes of disruption as metabolic priorities
• Magnesium glycinate 300 mg before bed

Weekly targets:

• Two to three resistance training sessions with progressive overload
• 150 minutes of moderate aerobic activity
• Consider two to three HIIT sessions for accelerated metabolic benefit
• Alcohol: minimal; alcohol significantly impairs hepatic glucose regulation and worsens insulin resistance
• Eating window: aim for 10–12 hours maximum (e.g., 8am–6pm or 8am–8pm)

Clinical assessment – request from your GP or endocrinologist:

• Fasting glucose and HbA1c at least annually from perimenopause onset
• Fasting insulin and HOMA-IR if fasting glucose is borderline or rising
• Fasting lipid panel with triglycerides
• Waist circumference measurement (target below 80 cm)
• Liver function tests (ALT)

Medical conversations to have:

• Discuss MHT as a metabolic intervention alongside other indications
• If HbA1c is above 5.7%: formal dietary counselling from a registered dietitian with diabetes expertise
• If HbA1c is above 6.0%: discuss GLP-1 receptor agonists and/or metformin with endocrinologist or GP
• If established type 2 diabetes: review medications at menopause, as hormone-related changes in insulin sensitivity will alter medication requirements

The Conclusion

The metabolic transition of perimenopause and menopause is one of the most clinically significant and least discussed health changes of this life stage. It is real, it is measurable, and it creates a genuine window of elevated diabetes risk that is substantially modifiable with the right approach.

The evidence converges on a clear, multi-component strategy: a Mediterranean dietary pattern with low glycemic load, chrononutritional alignment of eating to the body’s insulin rhythm, adequate protein for muscle maintenance, progressive resistance training as the cornerstone exercise, post-meal walking as a daily habit, sleep optimization as a metabolic priority, targeted supplementation (particularly magnesium and berberine), and for appropriate candidates, the combination of hormone therapy and – where indicated – GLP-1 receptor agonists.

None of these interventions alone is sufficient. All of them, consistently applied, produce meaningful protection against the progression from insulin resistance through prediabetes to type 2 diabetes – and meaningfully reduce the cardiovascular risk that travels alongside that progression.

You do not have to accept the deterioration in metabolic health that perimenopause makes possible. You do have to understand it, and respond to it – early, consistently, and with the full toolkit that the evidence supports.

For more useful articles and expert guidance, explore the Womeno app – your personal digital companion through the hormonal transition. Download the app HERE

Source

1. Franciscan Health / Clark MD. Menopause, Insulin Resistance & Diabetes Risk. franciscanhealth.org. April 2026.
2. Mauvais-Jarvis F et al. Menopausal Hormone Therapy and Type 2 Diabetes Prevention: Evidence, Mechanisms, and Clinical Implications. Endocrine Reviews. 2017;38(3):173–188. doi:10.1210/er.2016-1146
3. The Menopause Society. New Meta-Analysis Shows That Hormone Therapy Can Significantly Reduce Insulin Resistance. menopause.org. September 10, 2024. (17 RCTs, 29,000+ participants, presented at TMS Annual Meeting Chicago)
4. The Menopause Society. Diabetes Risk Not Associated With Timing or Type of Menopause.menopause.org. January 14, 2026.
5. Choi MJ, Yu J. Menopause and Diabetes Risk Along with Trajectory of β-Cell Function and Insulin Sensitivity: A Community-Based Cohort Study. Healthcare. 2025;13(9):1062. PMC12071248. doi:10.3390/healthcare13091062
6. Paschou SA et al. Menopausal Hormone Therapy in Women with Type 2 Diabetes Mellitus: An Updated Review. Diabetes Therapy. 2024;15(4):741–748. doi:10.1007/s13300-024-01546-1
7. Leiva Balich L et al. The interplay between diabetes mellitus and menopause: clinical implications.Nature Reviews Endocrinology. 2022. doi:10.1038/s41574-022-00715-z
8. PMC12842199. The Impact of the Menopausal Transition on Body Composition and Abdominal Fat Redistribution. MDPI. 2025.
9. American Journal of Pathology. The Role of Estrogen in Insulin Resistance. 2021. S0002-9440(21)00245-5.
10. Menopause Review. Association of age at menopause with type 2 diabetes mellitus in postmenopausal women: a systematic review and meta-analysis. 2024;23(4):205–217. doi:10.5114/pm.2024.145954
11. Revital Gorodeski Baskin, Kimberly A Karp. Navigating the Spectrum of 4 Evidence-Based Nutrition Options for Type 2 Diabetes Management. JCEM. 2025;110(Suppl 2):S112–S117. doi:10.1210/clinem/dgae646
12. PMC11007410. Systematic review of mediterranean diet interventions in menopausal women. Public Health. 2024. doi:10.3934/publichealth.2024005
13. CNN Health / Hu B. Mediterranean diet plus exercise and support reduced risk of diabetes by 31%. cnn.com. August 2025.
14. Discover Food (Springer). New insight on dietary strategies to increase insulin sensitivity and reduce diabetes prevalence: an expert perspective. 2025. doi:10.1007/s44187-025-00422-6
15. PMC8878449. Effects of Diet, Lifestyle, Chrononutrition and Alternative Dietary Interventions on Postprandial Glycemia and Insulin Resistance. Nutrients. 2022.
16. PMC12277773. Integrated strategies for type 2 diabetes prevention: The role of diet and exercise. Nutrients. 2025. doi:10.3390/nu17122100
17. PMC12052274. Intermittent Fasting and Weight Management at Menopause. Journal of Mid-life Health. 2025.
18. PMC10781045. Comparative Evaluation of a Low-Carbohydrate Diet and a Mediterranean Diet in Overweight/Obese Patients with T2DM: A 16-Week Intervention Study. Nutrients. 2024. doi:10.3390/nu16010139
19. Yahoo Health / Dr. Mary Claire Haver. A Game-Changing Duo for Midlife Weight Gain. 2025. (Citing: 2024 Menopause study semaglutide + HT)
20. Lovejoy JC et al. Increased visceral fat and decreased energy expenditure during the menopausal transition.International Journal of Obesity. 2008;32(6):949–958. PMC2748330.